June Sees Surge in Pharma Investment: Jetta Therapeutics, Andicon Bio, and Others Secure Over $100M Each

　　【Pharmaceutical Network Industry DynamicsSince June, the pharmaceutical sector has seen active investment and financing. Among them, METiS TechBio, Andikang (Wuxi) Biotechnology Co., Ltd., Kathon Biotech, Saiqiao Biotech, and Ruilong Norassign have each secured financing exceeding 100 million yuan.
 

Among them, METiS TechBio, an innovative biotechnology company focusing on "AI + drug delivery," recently announced the completion of its $100 million Series C financing. The company will use the proceeds from this round of financing to further strengthen team building and promote the research and development and clinical application of more innovative drugs.
 

Data shows that METiS TechBio leverages AI-driven precision-targeted drug delivery and drug discovery, focusing on the development of innovative nanomaterials and creating more effective therapeutic drugs for patients. The proceeds from this round of financing will mainly be used to further advance the construction of the AI + drug delivery platform and the development of its self-owned pipeline, supporting METiS TechBio's continuous innovation in the field of drug delivery.
 

Industry insiders say that in the development of CGT and mRNA drugs, "drug delivery" technology is a "choke point" to ensure their smooth entry into cells for expression, involving key issues such as targeting tissues and organs, efficient intracellular delivery, and endosomal escape.
 

As an enterprise in the "AI + Drug Delivery" field, METiS TechBio has independently developed three major AI+ core technology platforms: an AI-driven nucleic acid delivery system design platform, an AI-driven mRNA sequence design platform, and an AI-driven small molecule formulation design platform. It has also established a proprietary technical route for METiS TechBio that deeply integrates dry and wet experiments, thereby achieving efficient drug delivery and drug discovery.
 

Relying on these technology platforms, METiS TechBio has established several R&D pipelines, covering small molecule drugs and nucleic acid drugs mainly based on mRNA, with a focus on indications such as cancer, central nervous system diseases, and liver diseases. Currently, METiS TechBio's fastest progressing small molecule pipeline entered phase III clinical trials in June 2023, and the mRNA immunotherapy pipeline is expected to enter clinical trials this year.
 

Recently, Andikang (Wuxi) Biotechnology Co., Ltd. officially announced the completion of an over 200 million yuan Series A financing round. The funds raised will be used for the preclinical and clinical development of the company's core product pipeline, particularly to accelerate the pediatric clinical trials and commercialization progress of its self-developed anti-influenza Class 1 new drug, Mavdenoxavir (code name ADC189), in both tablet and granule forms.
 

Data shows that Andikang (Wuxi) Biotechnology Co., Ltd. is an innovative pharmaceutical enterprise focused on developing groundbreaking therapeutic drugs in the fields of respiratory infections and pain management. The company has established high technical barriers at various stages of new drug creation, including innovative drug design and synthesis, DMPK technology research and application, and the research and development of advanced formulations suitable for special populations. It has developed a small-molecule innovative therapeutic drug R&D system based on metabolic differentiation. Its core pipeline, the "one-pill cure" flu drug Mavidenosvir, has achieved significant clinical progress. In addition to the anti-flu drug Mavidenosvir pipeline, the company's product portfolio also includes several innovative drugs targeting respiratory pathogens, such as ADC789 Suspension for treating Respiratory Syncytial Virus (RSV), ADC101 Suspension, a novel anti-mycoplasma super-antibiotic, and ADC308 Tablets for treating endometriosis and uterine fibroids.
 

In addition, Ruifuxin Pharmaceuticals recently completed the initial closing of its Series A financing round, with a total Series A funding amount reaching $28 million. The proceeds will be used to advance the development of its Rapafusyn macrocyclic peptide-based non-degradable molecular glue technology platform and to progress its innovative drug pipeline targeting a wide range of disease categories, further enhancing its internal new drug R&D capabilities. Data shows that Ruifuxin Pharmaceuticals is an innovative drug developer specializing in non-degradable molecular glues and is a next-generation bifunctional macrolide drug R&D platform company.
 

Kaituo Biotech announced in June the completion of a new round of financing worth nearly 100 million yuan. The funds will be used to upgrade Kaituo Biotech's overseas business and full-process service capabilities, strengthening the company’s core competitiveness in the nucleic acid drug technology sector. Data shows that Kaituo Biotech is an innovative technology company focusing on the development and application of new biopharmaceutical technologies. It aims to provide one-stop services covering the entire industrial chain for gene and cell therapy drugs and nucleic acid drugs, from product development, quality research, and clinical applications to industrialization.
 

In June, Saichiao Bio announced the completion of a nearly 200 million yuan B-round financing. The funds will accelerate the commercialization process of new quality production equipment. Data shows that Saichiao Bio focuses on upstream key manufacturing technologies and complete sets of core equipment in the cell and gene therapy industry, engaging in original technological innovation and localization work. It is committed to breaking the import monopoly and providing the industry with a fully China-produced, independently controllable digital process equipment platform.
 

In June, RuiLong NuoFu completed a B-round financing of over 300 million RMB. This round of financing will accelerate the advancement of modular surgery.RobotThe commercialization process. Data shows that Ruilong Nuofu is an innovative medical technology company focusing on minimally invasive and digital surgery.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.